AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
EDIT
ACCE-researched

Editas Medicine Inc. Common Stock (EDIT) fair value

Healthcare · Biotechnology · NASDAQ · United States
$2.40-3.61%
Market cap $382MNext earnings 2026-11-09Updated Oct 20, 2026
Add earnings to calendarGoogle
Our verdict
Trades 133% above our fair value
Price
$2.40
Model fair valueConfidence: low
about $1.03
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps, Analyst consensus, and Net cash floor.
ACCE opinionEditas Medicine Inc. Common Stock (EDIT)
Fair value
Not available
ACCE price target
$2.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 18 Oct 2026, 01:52 CEST; previously $2.60 since 1 Oct 2026, 00:00 CEST.
Price used: $2.40 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus, Net cash floor, and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
29
out of 100
Analysts
69% buy
13 covering
P/E
0.0x
forward -3.2x
1-year return
-34.2%
Dividend yield
0.00%

Editas Medicine Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Editas Medicine develops CRISPR-based gene-editing medicines, with a focus on in vivo treatments for blood disorders and other genetic diseases. It holds foundational CRISPR patents, which may bring licensing value. The catalyst is early clinical data from its in vivo programmes. Revenue grew 232.3% from a tiny base, but the operating margin is -167.3% and ROE is -118.8%.

AI-assisted·How I use AIWritten Oct 14, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • severe
    Massive operating losses
    Operating margin -167.3%, net margin -157.3%, ROE -118.8%. Company burns cash at scale with negative gross margin -80.7%.
  • high
    Negative free cash flow
    FCF -$44.3M annually. Unsustainable cash burn despite 232% revenue growth signals pre-commercialization or failed product economics.
  • high
    High short interest
    19.5% short interest combined with severe unprofitability and negative FCF suggests market skepticism on path to viability.
  • moderate
    Valuation disconnect
    ACCE fair value $2.60 vs current $2.90. Stock trades above model estimate despite -157% net margin and ongoing losses.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue surged 232.3% year over year, demonstrating commercial traction and market acceptance of the company's approach.
  • Analyst consensus rates 62% of coverage as Buy or Strong Buy, with a mean price target implying 110.3% upside.
  • Latest earnings beat expectations by 50.0%, suggesting the company is executing better than the market anticipated.
Why it could disappoint
  • Net margin of negative 157.3% and free cash flow burn of 44M annually show the company is far from profitability.
  • Diluted share count rose 7.8% last fiscal year, and negative free cash flow yield of 10.0% signals ongoing dilution ahead.
  • Five year average revenue growth of only 27.1% per year pales against the recent 232.3% spike, raising sustainability questions.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where EDIT's valuation models land
Price
$2.40
Model fair valueConfidence: low
about $1.03
Model
Fair value
Upside
Analyst consensus
Net cash floor
Sales comps
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish69% buy · 13 covering analysts
● Strong buy 9● Buy 0● Hold 2● Sell 2● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+2.1%
1 month
-10.8%
3 months
-7.7%
6 months
-17.5%
YTD
+17.1%
1 year
-34.2%

SEC filings

Recent ACCE blog coverage

  • $EDIT ACCE Score Jumps 18 Points to 49 on Momentum Surge
    Editas Medicine's ACCE composite score rose from 31 to 49. Here's what's driving the move and what the subscore breakdown tells us about $EDIT right now.
    2026-08-12

Recommendation history, last 12 months

DateTypeNewPreviousPrice
18 Oct 2026, 01:52 CESTACCE price target$2.00$2.60$2.35
1 Oct 2026, 00:00 CESTACCE price target$2.60first publication$2.59

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full EDIT page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth64Value11Quality17Momentum23Total29
Valuation
Trailing P/E
0.0x
Forward P/E
-3.2x
PEG
no data
P/B
3.89x
EV / Revenue
4.6x
Book value/sh
$0.69
Enterprise value
$214M
Profitability
ROE
-118.8%
FCF yield
-43.37%
ROIC
no data
Health and risk
Debt / equity
2.81
Dividend yield
0.00%
Beta
2.00

Price

-26.2% · 1Y

Ask anything about EDIT

Answered from Editas Medicine Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 254.2x
ROEbetter than 0% of peers
low -119%-119%high 20%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 0.7%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
EDIT Editas Medicine Inc. Common Stock$2.40----118.8%1729
ZEAL.CO Zealand Pharma A/Skr 226.00--5.7x16.3%9051
BIOA-B.ST BioArctic AB (publ)kr 300.00kr 25916% above254.2x5.2%6238
BAVA.CO Bavarian Nordic A/Skr 247.40kr 37835% below12.7x12.2%8686
CAMX.ST Camurus AB (publ)kr 666.00kr 325105% above58.8x15.9%9055
BIOCON.NS Biocon Limited₹323.50--95.7x-6752
KRYS Krystal Biotech Inc. Common Stock$311.50$153104% above39.0x20.1%9571

Sector report card

Where EDIT ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 8, 2026
    Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
  • GlobeNewswire•Sep 9, 2026
    Editas Medicine Reports Inducement Grants to New Chief Medical Officer
  • GlobeNewswire•Sep 8, 2026
    Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
10 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 8
8-KCurrent reportPeriod 2026-10-08
View on SEC →
September 2026
Sep 9
Form 4Insider transactionPeriod 2026-09-08
View on SEC →
Sep 4
Form 4Insider transactionPeriod 2026-09-03
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR